Abstract
To assess potential risks related to the duration or total amount of fetal methadone exposure during gestation, we compared babies of women who conceived and maintained on methadone throughout pregnancy with babies of women who began methadone treatment during the second or third trimester. Babies conceived on methadone were exposed to the medication for a mean of 37.4 weeks at a mean dose of 110 mg/day, whereas comparison babies were exposed for a mean of 13.1 weeks at a mean dose of 93 mg/day. There were no significant between-group differences in the frequency of treatment of neonatal abstinence, days hospitalized, birth weight, or gestational age. Babies conceived on methadone were significantly less likely to test positive for illicit drugs at delivery as compared with babies conceived off methadone (positive toxicology, 9.1% vs. 34.3%, respectively). Methadone exposure during the entire gestational period was associated with better drug-treatment outcomes but was not associated with more severe neonatal abstinence.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 202-206 |
| Number of pages | 5 |
| Journal | Journal of Substance Abuse Treatment |
| Volume | 35 |
| Issue number | 2 |
| DOIs | |
| State | Published - Sep 2008 |
Fingerprint
Keywords
- Conception
- Drug treatment
- Methadone
- Neonatal abstinence
- Pregnancy
ASJC Scopus subject areas
- Psychiatry and Mental health
- Neuroscience(all)
Cite this
Outcomes of neonates conceived on methadone maintenance therapy. / McCarthy, John J.; Leamon, Martin H; Stenson, Garrett; Biles, Lagen A.
In: Journal of Substance Abuse Treatment, Vol. 35, No. 2, 09.2008, p. 202-206.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Outcomes of neonates conceived on methadone maintenance therapy
AU - McCarthy, John J.
AU - Leamon, Martin H
AU - Stenson, Garrett
AU - Biles, Lagen A.
PY - 2008/9
Y1 - 2008/9
N2 - To assess potential risks related to the duration or total amount of fetal methadone exposure during gestation, we compared babies of women who conceived and maintained on methadone throughout pregnancy with babies of women who began methadone treatment during the second or third trimester. Babies conceived on methadone were exposed to the medication for a mean of 37.4 weeks at a mean dose of 110 mg/day, whereas comparison babies were exposed for a mean of 13.1 weeks at a mean dose of 93 mg/day. There were no significant between-group differences in the frequency of treatment of neonatal abstinence, days hospitalized, birth weight, or gestational age. Babies conceived on methadone were significantly less likely to test positive for illicit drugs at delivery as compared with babies conceived off methadone (positive toxicology, 9.1% vs. 34.3%, respectively). Methadone exposure during the entire gestational period was associated with better drug-treatment outcomes but was not associated with more severe neonatal abstinence.
AB - To assess potential risks related to the duration or total amount of fetal methadone exposure during gestation, we compared babies of women who conceived and maintained on methadone throughout pregnancy with babies of women who began methadone treatment during the second or third trimester. Babies conceived on methadone were exposed to the medication for a mean of 37.4 weeks at a mean dose of 110 mg/day, whereas comparison babies were exposed for a mean of 13.1 weeks at a mean dose of 93 mg/day. There were no significant between-group differences in the frequency of treatment of neonatal abstinence, days hospitalized, birth weight, or gestational age. Babies conceived on methadone were significantly less likely to test positive for illicit drugs at delivery as compared with babies conceived off methadone (positive toxicology, 9.1% vs. 34.3%, respectively). Methadone exposure during the entire gestational period was associated with better drug-treatment outcomes but was not associated with more severe neonatal abstinence.
KW - Conception
KW - Drug treatment
KW - Methadone
KW - Neonatal abstinence
KW - Pregnancy
UR - http://www.scopus.com/inward/record.url?scp=47349115833&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=47349115833&partnerID=8YFLogxK
U2 - 10.1016/j.jsat.2007.09.009
DO - 10.1016/j.jsat.2007.09.009
M3 - Article
C2 - 18077124
AN - SCOPUS:47349115833
VL - 35
SP - 202
EP - 206
JO - Journal of Substance Abuse Treatment
JF - Journal of Substance Abuse Treatment
SN - 0740-5472
IS - 2
ER -